Lupin Ltd has launched Formoflo-G MDI, a new inhaler for chronic obstructive pulmonary disease management in India. This fixed-dose inhaler combines three therapies into a single device for better treatment outcomes. It aims to benefit over 55 million people living with COPD across the country. The Drug Controller General of India has approved this innovative product for use. Lupin is currently ranked second in the respiratory therapy segment in India.
Read more at The Economic Times
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.